Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia - CME - Guideline Central

CME

Title
Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia
Link
Description
On November 8, 2024, the US Food and Drug Administration (FDA) approved obecabtagene autoleucel (AUCATZYL, Autolus Inc) for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).1 Obecabtagene autoleucel is a CD19-directed genetically modified autologous T-cell immunotherapy composed of autologous T cells, transduced with a lentiviral vector to express an anti-CD19 chimeric antigen receptor (CAR). Herein, we summarize the FDA review and provide regulatory considerations regarding this approval.
Target Audience
Physicians
Learning Objectives
  • To identify the key insights or developments described in this article
Estimated Duration
60 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Oncology, Internal Medicine - General, Family Medicine, Critical Care, Primary Care
Professions
Physician
Keywords
leukemia
Disclosures and Disclaimers
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accredited Providers
  • Accreditation Council for Continuing Medical Education
Activity Expiration Date
February 10, 2028
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit1 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.